Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016', provides in depth analysis on Hepatitis B Virus Core Antigen (HBcAg) targeted pipeline therapeutics. 

The report provides comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis B Virus Core Antigen (HBcAg)
- The report reviews Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Hepatitis B Virus Core Antigen (HBcAg)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis B Virus Core Antigen (HBcAg) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatitis B Virus Core Antigen (HBcAg) Overview 6
Therapeutics Development 7
Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Stage of Development 7
Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Therapy Area 8
Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Indication 9
Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Companies 12
Hepatitis B Virus Core Antigen (HBcAg) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Hepatitis B Virus Core Antigen (HBcAg) - Companies Involved in Therapeutics Development 18
Abivax S.A. 18
F. Hoffmann-La Roche Ltd. 19
Gilead Sciences, Inc. 20
Transgene SA 21
VLP Biotech, Inc. 22
Hepatitis B Virus Core Antigen (HBcAg) - Drug Profiles 23
ABX-203 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
GS-4774 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
hepatitis B vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
RG-7944 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
TG-1050 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Hepatitis B Virus Core Antigen (HBcAg) - Dormant Projects 31
Hepatitis B Virus Core Antigen (HBcAg) - Featured News & Press Releases 32
Dec 08, 2015: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B 32
Nov 04, 2015: Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection 33
May 27, 2015: GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients 33
Apr 23, 2015: Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress 2015 34
Apr 21, 2015: Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection 34
Feb 26, 2015: ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 35
Jul 01, 2014: Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B 36
Nov 05, 2013: Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences 36
Apr 29, 2013: Transgene Presents Positive Preclinical Data On TG1050 To Treat Chronic HBV At EASL 2013 37
Apr 08, 2013: Transgene To Present New Data On TG1050 To Treat Chronic Hepatitis B At EASL 2013 Conference 38
Jan 28, 2013: GlobeImmune Initiates Phase Ia Clinical Trial Of GI-13020 In Healthy Volunteers 38
Nov 12, 2012: Inovio Pharma's Hepatitis B Vaccine Demonstrates Potential To Clear Hepatitis B Virus In Liver In Preclinical Study 39
Nov 12, 2012: Inovio Pharma's Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential To Clear HBV In Liver 39
Apr 19, 2012: Transgene's New Therapeutic Vaccine Candidate to Treat Chronic Hepatitis B Reaches Preclinical Proof of Concept 40
Oct 10, 2011: Inovio Pharma And VGX International To Advance Therapeutic Hepatitis C And Hepatitis B Synthetic Vaccines Into Clinical Studies 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Route of Administration, H1 2016 15
Number of Products by Stage and Molecule Type, H1 2016 17
Pipeline by Abivax S.A., H1 2016 18
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19
Pipeline by Gilead Sciences, Inc., H1 2016 20
Pipeline by Transgene SA, H1 2016 21
Pipeline by VLP Biotech, Inc., H1 2016 22
Dormant Projects, H1 2016 31